Early Experiences and Clinical Implications of Drug-Eluting Stents: Part 1

Annals of Pharmacotherapy

Volumn 38, Issue 4, 2004, Pages 661-669

  Chong, Pang H ^a,b,c   Cheng, Judy W M ^d,e  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b MIDWESTERN UNIVERSITY   (United States)

^c Department of Ambulatory and Community Health   (United States)

^d LONG ISLAND UNIVERSITY   (United States)

^e MOUNT SINAI MEDICAL CENTER   (United States)

Author keywords

Percutaneous coronary intervention; Restenosis; Stenting

Indexed keywords

ABT 578; ALPHA CYANO 3 ETHOXY 4 HYDROXY 5 (PHENYLTHIOMETHYL)CINNAMAMIDE; ANGIOPEPTIN; ANTISENSE OLIGODEOXYNUCLEOTIDE; BATIMASTAT; COLLAGEN; CYCLOSPORIN; DACTINOMYCIN; DEXAMETHASONE; ESTROGEN; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; HIRUDIN; ILOPROST; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD34; MYC PROTEIN; NITRIC OXIDE SYNTHASE INHIBITOR; PACLITAXEL; PREDNISOLONE; PROSTACYCLIN; RAPAMYCIN; STATIN; TACROLIMUS; TAXANE DERIVATIVE; TRANILAST; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; ARTERY INJURY; ARTERY INTIMA PROLIFERATION; BIOCOMPATIBILITY; BIODEGRADABILITY; CORONARY ARTERY OBSTRUCTION; CORONARY STENT; DRUG ACTIVITY; DRUG COATING; DRUG DELIVERY SYSTEM; DRUG ELUTING STENT; DRUG FORMULATION; EQUIPMENT DESIGN; EXPERIENCE; EXTRACELLULAR MATRIX; HUMAN; MACROPHAGE; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RESTENOSIS; REVIEW; RISK FACTOR; SUSTAINED RELEASE PREPARATION; TRANSLUMINAL CORONARY ANGIOPLASTY;

CLINICAL TRIALS; CORONARY RESTENOSIS; HUMANS; MYOCARDIAL REVASCULARIZATION; PHARMACEUTICAL PREPARATIONS; RISK FACTORS; STENTS;

EID: 1542534425     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1D256     Document Type: Review

References (45)

1. Holmes DR. State of the art in coronary intervention. Am J Cardiol 2003;91(suppl):50A-3A.
2. Holmes DR Jr, Vlietstra RE, Smith HC, Vetrovec GW, Kent KM, Cowley MJ, et al. Restenosis after percutaneous transluminal coronary angioplasty (PTCA): a report from the PTCA Registry of the National Heart, Lung, and Blood Institute. Am J Cardiol 1984:53(suppl):77C-81C.
3. Gruntzig AR, Senning A, Siegenthaler WE. Non-operative dilation of coronary artery stenosis. N Engl J Med 1979;301:61-8.
4. 2002 Heart and stroke statistical update. Dallas: American Heart Association, 2001.
5. Serruys PW, de Jaegere P, Kiemeneij F, Macaya C, Rutsch W, Heyndrickx, et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. N Engl J Med 1994;331:489-95.
6. Fischman DL, Leon MB, Baim DS, Schatz RA, Savage MP, Pena IM, et al. A randomized comparison of coronary stent placement and balloon angioplasty in the treatment of coronary artery disease. N Engl J Med 1994;331:496-501.
7. Fattori R, Piva T. Drug-eluting stents in vascular intervention. Lancet 2003;361:247-9.
8. Bennett MR, O'Sullivan M. Mechanism of angioplasty and stent restenosis: complications for design of rationale therapy. Pharmacol Ther 2001;91:149-66.
9. Williams DO, Holubkov R, Yeh W, Bourassa MG, Al-Bassam M, Black PC, et al. Percutaneous coronary interventions in the current era compared with 1985-1986: the National Heart, Lung and Blood Institute Registries. Circulation 2000;102:2945-51.
10. Mehran R, Dangas G, Abizaid AS, Mintz GS, Lansky AJ, Satler LF, et al. Angiographic patterns of in-stent restenosis: classification and implications for long-term clinical outcomes. Circulation 1999;100:1872-8.
11. Virmani R, Kolodgie FD, Farb A, Lafont A. Drug eluting stents: are human and animal studies comparable? Heart 2003;89:133-8.
12. Bennett MR. In-stent stenosis: pathology and implications for the development of drug eluting stents. Heart 2003;89:218-24.
13. Altmann DB, Racz M, Battleman DS, Bergman G, Spokojny A, Hannan EL, et al. Reduction in angioplasty complications after the introduction of coronary stents: results from a consecutive series of 2242 patients. Am Heart J 1996;132:503-7.
14. Lindsay J, Hong MK, Pinnow EE, Pichard AD. Effects of endoluminal coronary stents on the frequency of coronary artery bypass grafting after successful percutaneous transluminal coronary revascularization. Am J Cardiol 1996;77:647-9.
15. Savage MP, Douglas JS Jr, Fischman DL, Pepine CJ, King SB 3rd, Werner JA, et al. Stent placement compared with balloon angioplasty for obstructed coronary bypass grafts: Saphenous Vein De Novo Trial Investigators. N Engl J Med 1997;337:740-7.
16. Erbel R, Haude M, Hopp H, Franzen D, Rupprecht HJ, Heublein B, et al. Coronary-artery stenting compared with balloon angioplasty for restenosis after initial balloon angioplasty. Restenosis Stent Study Group. N Engl J Med 1998;339:1672-8.
17. Dzavik V. New frontiers and unresolved controversies in percutaneous coronary interventions. Am J Cardiol 2003;91(suppl A):27A-33A.
18. Welt FGP, Rogers C. Inflammation and restenosis in the stent era. Arterioscler Thromb Vasc Biol 2002;22:1769-76.
19. Shah PK. Inflammation, neointimal hyperplasia, and restenosis: as the leukocytes roll, the arteries thicken. Circulation 2003;107:2175-7.
20. Mintz GS, Popma JJ, Pichard AD, Kent KM, Satler LF, Wong C, et al. Arterial remodeling after coronary angioplasty: a serial intravascular ultrasound study. Circulation 1996;94:35-43.
21. Hoffmann R, Mintz GS, Dussaillant GR, Popma JJ, Pichard AD, Satler LF, et al. Patterns and mechanisms of in-stent restenosis: a serial intravascular ultrasound study. Circulation 1996;94:1247-54.
22. Inoue T, Sohma R, Miyazaki T, Iwasaki Y, Yaguchi I, Morooka S. Comparison of activation process of platelets and neutrophils after coronary stent implantation versus balloon angioplasty for stable angina pectoris. Am J Cardiol 2000;86:1057-62.
23. Rogers C, Welt FGP, Karnovsky MJ, Edelman ER. Monocyte recruitment and neointimal hyperplasia in rabbits: coupled inhibitory effects of heparin. Arterioscler Thromb Vasc Biol 1996;16:1312-8.
24. Welt FGP, Edelman ER, Simon DI, Rogers C. Neutrophil, not macrophage, infiltration precedes neointimal thickening in balloon-injured arteries. Arterioscler Thromb Vas Biol 2000;20:2553-8.
25. Horvath C, Welt FG, Nedelman M, Rao P, Rogers C. Targeting CCR2 or CD18 inhibit experimental in-stent restenosis in primates: inhibitory potential depends on type of injury and leukocytes targeted. Cir Res 2002;90:488-94.
26. Paolini JF, Kjelsberg MA, Edelman ER, Rogers CDK. Sustained expression of chemokines monocyte chemoattractant protein-1 and interleukin-8 after stent-but not balloon-induced arterial injury (abstract). J Am Coll Cardiol 2000;35:15.
27. Schwartz RS, Huber KC, Murphy JG, Edwards WD, Camrud AR, Vlietstra RE, et al. Restenosis and the proportional neointimal response to coronary artery injury: results in a porcine model. J Am Coll Cardiol 1992;19:267-74.
28. Schwartz RS, Murphy JG, Edwards WD, Camrud AR, Vlietstra RE, Holmes DR. Restenosis after balloon angioplasty. A practical proliferative model in porcine coronary arteries. Circulation 1990;82:2190-200.
29. Komatsu R, Ueda M, Naruko T, Kojima A, Becker AE. Neointimal tissue response at sites of coronary stenting in humans: macroscopic, histological, and immunohistochemical analyses. Circulation 1998;98:224-33.
30. Waller BF, Pinkerton CA, Orr CM, Slack JD, Van Tassel JW, Peters J, et al. Restenosis 1 to 24 months after clinically successful coronary balloon angioplasty: a necropsy study of 20 patients. J Am Coll Cardiol 1991;17(suppl B):58B-70B.
31. Smith SC Jr, Dove JT, Jacobs AK, Kennedy JW, Kereiakes D, Kern MJ, et al. ACC/AHA guidelines of percutaneous coronary intervention (revision of the 1993 PTCA guidelines)-executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (committee to revise the 1993 guidelines for percutaneous transluminal coronary angioplasty). J Am Coll Cardiol 2001;37:2215-39.
32. de Feyter PJ, Vos J, Rensing BJ. Anti-restenosis trials. Curr Interv Cardiol Rep 2000;2:326-31.
33. Farb A, Sangiorgi G, Carter AJ, Walley VM, Edwards WD, Schwartz RS, et al. Pathology of acute and chronic coronary stenting in humans. Circulation 1999;99:44-52.
34. Farb A, Weber DK, Kolodgie FD, Burke AP, Virmani R. Morphological predictors of restenosis after coronary stenting in humans. Circulation 2002;105:2974-80.
35. Schwartz RS, Edelman ER, Carter A, Chronos N, Rogers C, Robinson KA, et al. Drug-eluting stents in preclinical studies: recommended evaluation from a consensus group. Circulation 2002;106:1867-73.
36. Sousa JE, Serruys PW, Costa MA. New frontiers in cardiology: drug-eluting stents: part I. Circulation 2003;107:2274-9.
37. Finkelstein A, McClean D, Kar S, Takizawa K, Varghese K, Baek N, et al. Local drug delivery via a coronary stent with programmable release pharmacokinetics. Circulation 2003;107:777-84.
38. Ramen VK, Edelman ER. Coated stents: local pharmacology. Semin Intervent Cardiol 1998;3:133-7.
39. Sousa JE, Serruys PW, Costa MA. New frontiers in cardiology: drug-eluting stents: part II. Circulation 2003;107:2383-9.
40. Suzuki T, Kopia G, Hayashi S, Bailey LR, Llanos G, Wilensky R, et al. Stent-based delivery of sirolimus reduces neointimal formation in a porcine coronary model. Circulation 2001;104:1188-93.
41. Whelan DM, van Beusekom HM, van der Giessen WJ. Mechanisms of drug loading and release kinetics. Semin Interv Cardiol 1998;3:127-31.
42. Fox R. American Heart Association 2001 scientific sessions: late-breaking science-drug eluting stents. Circulation 2001;104:E9052.
43. Lovich MA, Creel C, Hong K, Hwang CW, Edelman ER. Carrier proteins determine local pharmacokinetics and arterial distribution of paclitaxel. J Pharm Sci 2001;90:1324-35.
44. ven der Giessen W, Lincoff AM, Schwartz RE, van Beusekom HM, Serruys PW, Holmes DR Jr, et al. Marked inflammatory sequelae to implantation of biodegradable and nonbiodegradable polymers in porcine coronary arteries. Circulation 1996;94:1690-7.
45. Drachman DE, Edelman ER, Seifert P, Groothuis AR, Bornstein DA, Kamath KR, et al. Neointimal thickening after stent delivery of paclitaxel: change in composition and arrest of growth over six months. J Am Coll Cardiol 2000;36:2325-32.